BREAKING NEWS: ASHP Files Amicus Brief in AstraZeneca and HHS Lawsuit in Support of 340B Program

ASHP and five national hospital organizations, in a continued effort to protect the 340B Drug Pricing Program, filed an amicus brief Tuesday in AstraZeneca's case against the Department of Health and Human Services (HHS) over the 340B Drug Pricing Program.

ASHP, 340B Health, the American Hospital Association, America’s Essential Hospitals, the Association of American Medical Colleges, and the Children’s Hospital Association took this important step in support of the HHS advisory opinion stating that manufacturers must provide 340B discounts to qualified health systems, including when a contracting pharmacy is used to dispense drugs.

“The 340B program continues to be a critical lifeline for ensuring that our most vulnerable populations have access to the care they need,” said Tom Kraus, ASHP vice president of government relations.

“HHS’s advisory opinion is unquestionably clear — drug manufacturers, including AstraZeneca, have a legal obligation to provide discounts to 340B-covered entities. ASHP remains committed to working with our partner organizations to demand that manufacturers stop trying to make up their own rules regarding pricing provided to 340B-covered entities and meet their obligations under the 340B program.”

ASHP will continue to keep our members informed on the ongoing 340B litigation and our aggressive advocacy on this critical program for our members and the patients they serve.